Clinical‑trial literature may contain a non‑trivial share of fabricated or irreproducible trials, so routine forensic audits (random raw‑data checks, statistical integrity screening and mandatory provenance deposits) should be implemented as a condition of publication and regulatory acceptance. Such audits would combine statistical forensics with mandatory access to trial records to catch fabricated datasets and prevent sham trials from informing care.
— If adopted, forensic auditing would shift where trust is placed—from reputation and peer review to verifiable data provenance—and could materially change drug approvals, clinical guidelines and patient safety.
Jake Currie
2026.10.05
63% relevant
The article highlights a methodological gap: senolytic drugs are often tested on artificially induced senescent cells from young animals, but this study shows aged senescent cells differ in protein‑recycling (CMA) and immune clearance. That maps to the existing concern about trial and evidence robustness and supports calls for deeper, audit‑style scrutiny of preclinical models and translational claims.
Kristen French
2026.09.17
64% relevant
Because the article raises a systemic risk that trial outcomes may be biased by unblinding, it strengthens the case for independent methodological scrutiny (forensic audits) of high‑stakes psychedelic trials before policy or approvals, linking the UCSF/Stanford/UCSD JAMA Psychiatry call to demands for trial auditing and transparency.
2023.07.18
100% relevant
Nature cites John Carlisle’s estimate and multiple investigations reporting that up to ~25% of trials in some fields may be problematic, and reports researchers urging stronger scrutiny and checks by journals and regulators.